Display options
Share it on

Indian J Otolaryngol Head Neck Surg. 2009 Dec;61(4):256-61. doi: 10.1007/s12070-009-0078-5. Epub 2010 Jan 09.

Assessment of aminoglycoside-induced hearing impairment in hospitalized neonates by TEOAE.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India

Mohammad Naeimi, Gholamali Maamouri, Hassan Boskabadi, Sadegh Golparvar, Mohamadreza Taleh, Habib Esmaeeli, Javad Khademi

Affiliations

  1. Ghaem Hospital, Mashhad University of Medical Sciences (MUMS), Mashhad, Iran.

PMID: 23120646 PMCID: PMC3450078 DOI: 10.1007/s12070-009-0078-5

Abstract

CONTEXT: Aminoglycosides, as potent bactericidal antibiotics against aerobic gram-negative infections, is still widely used, especially in NICU patients, despite their known potential ototoxic effects.

AIMS: To evaluate the potential of transient evoked otoacoustic emissions (TEOAEs) in early identification of decreased hearing sensitivity in hospitalized neonates receiving aminoglycosides for severe gram-negative infections.

MATERIALS AND METHODS: Fifty (50) neonates treated with intravenous gentamicin (5 mg/kg/day) or amikacin (15 mg/kg/day) were tested with TEOAE in the beginning and the end of aminoglycoside therapeutic course. There were 23 males and 27 females, ranging from 29 to 40 weeks (mean: 36 weeks). The treatment duration was 3-30 days (in 26 neonates up to 7 days - group A, and in 24 neonates higher than 7 days - group B).

RESULTS: In group A, no statistically significant difference in the mean response level was found between the onset and the end of treatment course (p > 0.001). In group B, a statistically significant difference in the mean response level was found between the onset and the end of treatment course, especially at high frequency region (p < 0.001).

CONCLUSIONS: TEOAE is sensitive enough to detect early aminoglycoside ototoxicity. As this test is simple to perform, non-invasive and reliable, so we suggest that TEOAE test should be performed in NICU as routine for monitoring cochlear function to prevent permanent hearing loss especially in those who are receiving aminoglycoside for more than 7 days.

Keywords: Aminoglycoside; NICU; Neonates; Ototoxicity; TEOAE

References

  1. Hear Res. 1989 Nov;42(2-3):143-56 - PubMed
  2. J Antimicrob Chemother. 1984 Jan;13 Suppl A:9-22 - PubMed
  3. Hear Res. 1996 Sep 1;98(1-2):93-103 - PubMed
  4. Audiol Neurootol. 1998 Nov-Dec;3(6):361-72 - PubMed
  5. Scand Audiol Suppl. 1979;(9):83-92 - PubMed
  6. Int J Audiol. 2005 Jan;44(1):24-30 - PubMed
  7. Ann Otol Rhinol Laryngol. 1953 Dec;62(4):1128-48 - PubMed
  8. Hear Res. 1987;28(2-3):191-208 - PubMed
  9. Hear Res. 1987;28(2-3):173-89 - PubMed
  10. Brain Res Brain Res Rev. 1995 Jan;20(1):68-90 - PubMed
  11. Int J Pediatr Otorhinolaryngol. 1993 Oct;27(3):245-54 - PubMed
  12. Laryngoscope. 1994 Sep;104(9):1130-4 - PubMed
  13. Ann Otol Rhinol Laryngol. 1976 Nov-Dec;85(6 PT. 1):740-51 - PubMed
  14. Int J Pediatr Otorhinolaryngol. 1999 Nov 5;50(3):177-84 - PubMed
  15. J Acoust Soc Am. 1991 May;89(5):2027-67 - PubMed
  16. Arch Otolaryngol. 1970 Aug;92(2):160-2 - PubMed

Publication Types